HUA MEDICINE
華領藥業

(Stock Code: 2552)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022

Board Director Company Governance Reporting Period Project

BUSINESS HIGHLIGHTS

- 华堂宁 华堂宁
- 华堂宁
- 华堂宁
  华堂宁

–

华堂宁

β

–

华堂宁 华堂宁

华堂宁

–

华堂宁

–

华堂宁

华堂宁

–

南京盛德瑞爾醫藥科技有限公司 **A cendRa e**

华堂宁

β

华堂宁

华堂宁

β

华堂宁

华堂宁

华堂宁

华堂宁

华堂宁
华堂宁
华堂宁
华堂宁

Ca tiona S tatemen t e i ed nde R le 18A.08(3) of the Li ting R le :

Product Pipeline

Product Name	Indication	Development phase	Pre-clinical	IND	Phase I	Phase II	Phase III	NDA	Launched
HuaTangNing (华堂宁®)	T2D - monotherapy	Launched (China)							
	T2D - combination therapy with metformin	Launched (China)							
HuaTangNing (华堂宁®)	DKD	Launched (China) - Allowances							
	Combination therapy with DPP4i	Launched (China) - Allowances							
	Combination therapy with SGLT2i	Launched (China) - Allowances							
Fixed dose combinations - dorzagliatin and OADs	T2D	Phase I ready							
Next Generation of GKA	Metabolic Diseases	Pre-clinical							
Glucokinase compound	Congenital Hyperinsulinism	Pre-clinical							
Fructose Kinase Inhibitor	Metabolic Disease	Pre-clinical							
mGLUR5 NAM - CNS	PD-LID	Pre-clinical							

Business Outlook


华堂宁 华堂宁 华堂宁 华堂宁 华堂宁

Important Event after the Reporting Period

华堂宁 华堂宁

Financial Review

Review



6Ø/1

*O**t**he gain and lo e*

Research and development expenses

	For the year ended December 31, 2022	
	RMB'000	*%*
	4,928	**3.8%**
	4,368	**3.4%**
	9,765	**7.5%**
	84,341	**65.1%**
	2,453	**1.9%**
	23,673	**18.3%**
	129,528	**100.0%**

Income tax expense

Liquidity and capital resources

Cash Operating Cost

	For the year ended December 31, 2022 *RMB'000*
	110,433
	64,901
	49,390
	5,390
	119,681
	230,114

Ca h F lo

	For the year ended December 31, 2022 *RMB'000*
	(230,114)
	(4,752)
	21,476
	28,784
	(184,606)

Ne t Ca h U ed in O e a ing Ac i i ie

Net Cash Used in Investing Activities

Indeb$_t$edne

	A of Decembe 31, 2022 *RMB'000*
	55,413
	42,169
	97,582

	A of Decembe 31, 2022 *RMB'000*
Im ac t on ofi t o lo	
	(9,893)
	(2,250)

Cha ge of the G o ' a et

Ca ital commi tmen t

	A of Decembe 31, 2022 *RMB'000*
	1,107

F t e lan fo ma te ial in e tmen t o ca ital a et

Con tingen t liabili tie

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	For the year ended December 31,	
	2022	
	RMB'000	
	(audited)	
	17,599	–
	(9,910)	–
	7,689	–
	41,511	
	26,026	
	(129,931)	
	(3,667)	
	(15,348)	–
	(259)	
	(129,528)	
	(203,507)	
	–	
	(203,507)	
	94	
	(203,413)	
LOSS PER SHARE	*RMB*	
	(0.21)	

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	A of Decembe 31, 2022 *RMB'000* (a di ted)
Non-c en a e	
	53,855
	85,853
	31,952
	3,130
	6,450
	181,240
C en a e	
	1,915
	441,192
	1,822
	4,696
	490,632
	940,257
C en liabili ie	
	79,111
	33,923
	21,490
	43,303
	10,559
	188,386
Ne C en A e	**751,871**
To al A e Le C en Liabili ie	**933,111**
Non-c en liabili ie	
	42,169
	606,248
	5,114
	653,531
Ne A e	**279,580**

	A of Decembe 31, 2022 *RMB'000* (a di ed)
Ca i al and e e e	
	7,214
	(584)
	272,950
	279,580
To al E i	279,580

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. General information

2. Basis of preparation of the consolidated financial statements

3. Revenue

(i) Disaggregation of revenue from contracts with customers

	For the year ended December 31, 2022
	RMB'000
	(audited)
	17,599


(ii) Performance obligations for contracts with customers

4. Other income

	For the year ended December 31, 2022 *RMB'000* (audited)
	4,240
	26,445
	10,826
	–
	41,511

8. Income tax expense

9. Licence agreement



10. Lo ge ha e

	For the year ended December 31, 2022 *RMB'000* (audited)
	(203,507)

	For the year ended December 31, 2022 (audited)
	966,730,201

13. T ade and o t he ecei able

	A of Decembe 31, 2022 *RMB'000* (a di t ed)
	11,121
	3,969
	16,542
	603
	4,887
VAT	
	505
	1,133
	871
	744
	6,837
	430
	400,000
	447,642
	441,192
	6,450
	447,642

	A of Decembe 31, 2022 *RMB'000* (a di t ed)
	10,982
	139

14. Bank balance and cash/Pledged bank deposit

	A of Decembe 31, 2022 *RMB'000* (a di ed)
	196,872
	43,944
	3

15. Trade and other payable

	A of Decembe 31, 2022 *RMB'000* (a di ed)
	20,982
	2,553
	1,468
	9,828
	38,342
	5,906
	32
	79,111

15. T ade and o t he ga able – con t in ed

	A of Decembe 31, 2022 *RMB'000* (a di t ed)
	20,792
	190
	20,982

	A of Decembe 31, 2022 *RMB'000* (a di t ed)
	45

16. Bo o ing

	A of Decembe 31, 2022 *RMB'000* (a di t ed)
	33,923

17. Con$_t$ ac$_t$ liabili$_t$ie

	A of Decembe 31, 2022 *RMB'000* (a di$_t$ed)	
	649,551	
	43,303	
	606,248	
	649,551	

	% of e of p oceed	Ne t p oceed f om t he Global Offe ing	Un t ilized ne t p oceed a of Jan a 1, 2022	U t iliza t ion d ing t he ea ended Decembe 31, 2022	Ac t al age p t o Decembe 31, 2022	Un t ilized ne t p oceed a of Decembe 31, 2022	E pec ted t ime f ame fo n t ilized amo n t
To t al	100%	747.2	259.4	89.7	577.5	169.7	B t he end of ea 2024

F inal di idend

Sec i t ie t an ac t ion b t he Di ec t o

Model Code

Co p o a t e go e nance

Code

Re ie of ann al e l t

Sco e of Wo k of Me . Deloi tt e To che Tohma t

Ann al gene al mee ing and clo e of egi e of ha eholde

AGM

P blica ion of he ann al e l and 2022 ann al e o on he eb i e of he S ock E change and he Com an